{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:02:34Z","timestamp":1792800154933,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.esmorw.2025.100646","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:13:43Z","timestamp":1763691223000},"page":"100646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["JAVEMACS: a real-world study of avelumab maintenance therapy for advanced urothelial carcinoma in Japan"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-931X","authenticated-orcid":false,"given":"H.","family":"Kitamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ikarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Masumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Negishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yatsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Taoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shirotake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmorw.2025.100646_bib2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/iju.13955","article-title":"Impact of sex difference on survival of bladder cancer: a population-based registry data in Japan","volume":"26","author":"Nakayama","year":"2019","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100646_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"issue":"10","key":"10.1016\/j.esmorw.2025.100646_bib4","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.21037\/tau-20-1472","article-title":"Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review","volume":"10","author":"Giudici","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100646_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/iju.15362","article-title":"Summary of the clinical practice guidelines for upper tract urothelial carcinoma 2023 by the Japanese Urological Association","volume":"31","author":"Mori","year":"2024","journal-title":"Int J Urol"},{"issue":"13","key":"10.1016\/j.esmorw.2025.100646_bib7","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.esmorw.2025.100646_bib8","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100646_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10147-021-02067-8","article-title":"Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis","volume":"27","author":"Tomita","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmorw.2025.100646_bib10","article-title":"Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan","volume":"35","author":"Kikuchi","year":"2024","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.esmorw.2025.100646_bib11","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100646_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jnci\/djad246","article-title":"Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment","volume":"116","author":"Gupta","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100646_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104506","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients","volume":"10","author":"Gupta","year":"2025","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.esmorw.2025.100646_bib14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/iju.15473","article-title":"J-AVENUE: a retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan","volume":"31","author":"Kikuchi","year":"2024","journal-title":"Int J Urol"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100646_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102238","article-title":"Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the real-world US PATRIOT-II study","volume":"22","author":"Grivas","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"suppl 4","key":"10.1016\/j.esmorw.2025.100646_bib17","article-title":"Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la\/mUC) receiving avelumab first-line maintenance (1LM) in the US","volume":"42","author":"Moon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmorw.2025.100646_bib18","article-title":"READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma","volume":"5","author":"Antonuzzo","year":"2024","journal-title":"ESMO Real World Data Dig Oncol"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100646_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.euo.2024.09.014","article-title":"Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in France: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment","volume":"8","author":"Barthelemy","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100646_bib20","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/iju.15411","article-title":"Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan","volume":"31","author":"Kita","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.esmorw.2025.100646_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104352","article-title":"C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: a systematic review and meta-analysis","volume":"197","author":"Fujiwara","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"suppl 6","key":"10.1016\/j.esmorw.2025.100646_bib22","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy","volume":"41","author":"Sridhar","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125005351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125005351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:53:14Z","timestamp":1788670394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820125005351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":19,"alternative-id":["S2949820125005351"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100646","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAVEMACS: a real-world study of avelumab maintenance therapy for advanced urothelial carcinoma in Japan","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100646"}}